Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for VTE Prevention in Myeloma
NCT02066454Phase 3Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Jun 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apixaban in venous thromboembolism (VTE), sponsored by CHU Grenoble Alpes. Primary endpoints: Total VTE and VTE-related death at 7 months and Major and clinically relevant non major bleeding at 7 months. Started Jun 2014; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02066454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066454.